Investigating the Utility of comprehensive genomic Profiling for patients with newly diagnosed breast cancer.
Casey Williams(Creighton University), Brian Leyland‐Jones(Avera Health), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Amy Krie(Amgen (United States)), Kirstin Williams(Avera Health), Kimberly C. Banks(Guardant (United States)), Robert B. Goldberg(Trillium Health Centre), Benjamin Solomon(Avera Health), Brandon Young(Avera Health), Jeffrey S. Ross(Unknown), Siraj M. Ali(UPMC Hillman Cancer Center), Vincent A. Miller(Universidad San Carlos), Pradip De(Avera Health), Christine Elaine Lee(Guardant (United States)), Jessica Klein(Cancer Institute (WIA)), Nandini Dey(University of South Dakota)
Cited by 0
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726